UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 10-Q
x
Quarterly
Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the quarterly period ended March
31, 2012
¨
Transition
Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the transition period from________
to ________
Commission File Number: 0-19266
ALLIED
HEALTHCARE PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
25-1370721
|
(State or other jurisdiction of
|
(I.R.S. Employer
|
Incorporation or organization)
|
Identification No.)
|
1720 Sublette
Avenue, St. Louis, Missouri 63110
(Address of principal executive offices,
including zip code)
(314) 771-2400
(Registrant’s telephone number, including
area code)
N/A
(Former name, former address and former
fiscal year, if changed since last report)
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
twelve months (or for such shorter periods that the registrant was required to file such reports, and (2) has been subject to
such filing requirements for the past ninety days. Yes
x
No
¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes
x
No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of
"large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer
¨
|
|
Accelerated filer
¨
|
|
|
|
Non-accelerated filer
¨
|
(Do not check if smaller reporting company)
|
Smaller reporting company
x
|
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).
Yes
¨
No
S
The number of shares of common stock outstanding at April 30,
2012 is 8,124,386 shares.
INDEX
|
|
|
|
Page
|
|
|
Number
|
Part I –
|
Financial Information
|
|
|
Item 1.
|
Financial Statements Consolidated Statement of Operations - Three and nine months ended March 31, 2012 and 2011
(Unaudited)
|
3
|
|
|
|
|
|
|
Consolidated Balance Sheet - March 31, 2012 (Unaudited) and June 30, 2011
|
4 - 5
|
|
|
|
|
|
|
Consolidated Statement of Cash Flows - Nine months ended March 31, 2012 and 2011 (Unaudited)
|
6
|
|
|
|
|
|
|
Notes to Consolidated Financial Statements
|
7 – 11
|
|
|
|
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
11 – 16
|
|
|
|
|
|
Item 3.
|
Quantitative and Qualitative Disclosure about Market Risk
|
16
|
|
|
|
|
|
Item 4.
|
Controls and Procedures
|
16
|
|
|
|
|
Part II -
|
Other Information
|
|
|
|
|
|
|
Item 1.
|
Legal Proceedings
|
17
|
|
|
|
|
|
Item 1A.
|
Risk Factors
|
17
|
|
|
|
|
|
Item 6.
|
Exhibits
|
17-18
|
|
|
|
|
|
|
Signature
|
19
|
SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995
Statements contained in this Report, which
are not historical facts or information, are "forward-looking statements." Words such as "believe," "expect,"
"intend," "will," "should," and other expressions that indicate future events and trends identify
such forward-looking statements. These forward-looking statements involve risks and uncertainties, which could cause the outcome
and future results of operations, and financial condition to be materially different than stated or anticipated based on the forward-looking
statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting
the demand for and economic factors affecting the delivery of health care services, and specific matters which relate directly
to the Company's operations and properties as discussed in the Company’s annual report on Form 10-K for the year ended June
30, 2011. The Company cautions that any forward-looking statements contained in this report reflect only the belief of the Company
or its management at the time the statement was made. Although the Company believes such forward-looking statements are based
upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.
PART I.
FINANCIAL
INFORMATION
Item 1. Financial Statements
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
10,702,421
|
|
|
$
|
11,338,196
|
|
|
$
|
32,778,824
|
|
|
$
|
34,681,610
|
|
Cost of sales
|
|
|
8,377,307
|
|
|
|
8,729,823
|
|
|
|
25,312,756
|
|
|
|
26,712,541
|
|
Gross profit
|
|
|
2,325,114
|
|
|
|
2,608,373
|
|
|
|
7,466,068
|
|
|
|
7,969,069
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
2,555,649
|
|
|
|
2,494,806
|
|
|
|
7,883,631
|
|
|
|
7,780,116
|
|
Income (loss) from operations
|
|
|
(230,535
|
)
|
|
|
113,567
|
|
|
|
(417,563
|
)
|
|
|
188,953
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
(5,692
|
)
|
|
|
(8,150
|
)
|
|
|
(21,984
|
)
|
|
|
(23,692
|
)
|
Interest expense
|
|
|
-
|
|
|
|
-
|
|
|
|
336
|
|
|
|
66
|
|
Other, net
|
|
|
10,297
|
|
|
|
24,421
|
|
|
|
36,446
|
|
|
|
67,931
|
|
|
|
|
4,605
|
|
|
|
16,271
|
|
|
|
14,798
|
|
|
|
44,305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before provision for (benefit from) income taxes
|
|
|
(235,140
|
)
|
|
|
97,296
|
|
|
|
(432,361
|
)
|
|
|
144,648
|
|
Provision for (benefit from) income taxes
|
|
|
(89,353
|
)
|
|
|
36,972
|
|
|
|
(164,297
|
)
|
|
|
54,966
|
|
Net income (loss)
|
|
$
|
(145,787
|
)
|
|
$
|
60,324
|
|
|
$
|
(268,064
|
)
|
|
$
|
89,682
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share
|
|
$
|
(0.02
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share
|
|
$
|
(0.02
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.03
|
)
|
|
$
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - basic
|
|
|
8,124,386
|
|
|
|
8,113,434
|
|
|
|
8,124,386
|
|
|
|
8,101,643
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - diluted
|
|
|
8,124,386
|
|
|
|
8,195,174
|
|
|
|
8,124,386
|
|
|
|
8,121,042
|
|
See
accompanying Notes to Consolidated Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED BALANCE SHEET
ASSETS
|
|
(Unaudited)
|
|
|
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
6,375,285
|
|
|
$
|
6,512,887
|
|
Accounts receivable, net of allowances of $300,000
|
|
|
4,123,940
|
|
|
|
5,366,860
|
|
Inventories, net
|
|
|
10,338,003
|
|
|
|
10,553,289
|
|
Income tax receivable
|
|
|
-
|
|
|
|
95,578
|
|
Other current assets
|
|
|
665,404
|
|
|
|
213,745
|
|
Total current assets
|
|
$
|
21,502,632
|
|
|
$
|
22,742,359
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
9,307,647
|
|
|
|
8,660,507
|
|
Other assets, net
|
|
|
562,112
|
|
|
|
362,480
|
|
Total assets
|
|
$
|
31,372,391
|
|
|
$
|
31,765,346
|
|
See accompanying
Notes to Consolidated Financial Statements.
(CONTINUED)
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED BALANCE SHEET
(CONTINUED)
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
(Unaudited)
|
|
|
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
1,588,091
|
|
|
$
|
1,644,910
|
|
Other accrued liabilities
|
|
|
2,073,899
|
|
|
|
1,645,552
|
|
Deferred income taxes
|
|
|
499,417
|
|
|
|
512,572
|
|
Deferred revenue
|
|
|
286,750
|
|
|
|
688,200
|
|
Total current liabilities
|
|
|
4,448,157
|
|
|
|
4,491,234
|
|
|
|
|
|
|
|
|
|
|
Deferred revenue
|
|
|
-
|
|
|
|
114,700
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity:
|
|
|
|
|
|
|
|
|
Preferred stock; $0.01 par value; 1,500,000 shares
|
|
|
|
|
|
|
|
|
authorized; no shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Series A preferred stock; $0.01 par value; 200,000 shares
|
|
|
|
|
|
|
|
|
authorized; no shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878
shares issued at March 31, 2012 and June 30, 2011; 8,124,386 shares outstanding at March 31, 2012 and June 30, 2011
|
|
|
104,279
|
|
|
|
104,279
|
|
Additional paid-in capital
|
|
|
48,531,989
|
|
|
|
48,499,103
|
|
Accumulated deficit
|
|
|
(980,606
|
)
|
|
|
(712,542
|
)
|
Less treasury stock, at cost; 2,303,492 shares at
|
|
|
|
|
|
|
|
|
March 31, 2012 and June 30, 2011
|
|
|
(20,731,428
|
)
|
|
|
(20,731,428
|
)
|
Total stockholders' equity
|
|
|
26,924,234
|
|
|
|
27,159,412
|
|
Total liabilities and stockholders' equity
|
|
$
|
31,372,391
|
|
|
$
|
31,765,346
|
|
See accompanying Notes to Consolidated
Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(268,064
|
)
|
|
$
|
89,682
|
|
Adjustments to reconcile net income (loss) to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
948,245
|
|
|
|
1,070,981
|
|
Stock based compensation
|
|
|
32,886
|
|
|
|
15,928
|
|
Provision for doubtful accounts and sales returns and allowances
|
|
|
13,478
|
|
|
|
19,722
|
|
Deferred taxes
|
|
|
(221,970
|
)
|
|
|
(6,371
|
)
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
1,229,442
|
|
|
|
109,248
|
|
Inventories
|
|
|
215,286
|
|
|
|
(59,555
|
)
|
Income tax receivable
|
|
|
95,578
|
|
|
|
101,084
|
|
Other current assets
|
|
|
(451,659
|
)
|
|
|
(34,925
|
)
|
Accounts payable
|
|
|
(56,819
|
)
|
|
|
30,868
|
|
Deferred revenue
|
|
|
(516,150
|
)
|
|
|
(516,150
|
)
|
Other accrued liabilities
|
|
|
428,347
|
|
|
|
(271,665
|
)
|
Net cash provided by operating activities
|
|
|
1,448,600
|
|
|
|
548,847
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
|
(1,586,202
|
)
|
|
|
(125,815
|
)
|
Net cash used in investing activities
|
|
|
(1,586,202
|
)
|
|
|
(125,815
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Stock options exercised
|
|
|
-
|
|
|
|
103,250
|
|
Excess tax benefit from exercise of stock options
|
|
|
-
|
|
|
|
12,980
|
|
Net cash provided by financing activities
|
|
|
-
|
|
|
|
116,230
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(137,602
|
)
|
|
|
539,262
|
|
Cash and cash equivalents at beginning of period
|
|
|
6,512,887
|
|
|
|
5,263,324
|
|
Cash and cash equivalents at end of period
|
|
$
|
6,375,285
|
|
|
$
|
5,802,586
|
|
See accompanying
Notes to Consolidated Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1. Summary of Significant Accounting and Reporting Policies
Basis of Presentation
The accompanying unaudited
consolidated financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance
with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles
generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments,
consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results
for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should
be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements thereto included
in the Company’s Annual Report on Form 10-K for the year ended June 30, 2011.
Recently Adopted Accounting Pronouncements
In October 2009, the
Financial Accounting Standards Board (“FASB”) issued guidance titled “Revenue Recognition – Multiple Deliverable
Revenue Arrangements”, which requires entities to allocate revenue in an arrangement using estimated selling prices of the
delivered goods and services based on a selling price hierarchy. The guidance eliminates the residual method of revenue allocation
and requires revenue to be allocated using the relative selling price method. This guidance is applied on a prospective basis
for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. This guidance
became effective for the Company in the quarter ended September 30, 2010, and its adoption did not have a significant effect
on the Company’s consolidated financial statements.
In July 2010, the
FASB issued guidance expanding disclosure requirements related to receivables. The guidance was issued to provide financial statement
users with greater transparency about an entity’s allowance for credit losses and the credit quality of its financing receivables.
The guidance is for receivables, off-balance sheet credit exposures and foreclosed and repossessed assets. The Company’s
summary of significant accounting policies shall now include: (i) basis for accounting for loans, trade receivables, and lease
financing (including those classified as held for sale), (ii) method used in determining the lower of cost or fair value of nonmortgage
loans held for sale, (iii) classification and method of accounting for interest-only strips, loans and other receivables and (iv)
method for recognizing interest income on loan and trade receivables.
In addition, the allowance
for credit losses, the allowance for doubtful accounts, and as applicable any unearned income, any unamortized premiums and discounts,
and any net unamortized deferred fees and costs, shall be disclosed in the financial statements. The Company adopted this guidance,
as required for both interim and annual reporting periods, for the quarter ended December 31, 2010. The adoption of this guidance
does not impact the Company’s consolidated results of operations or financial position. The Company has included its Accounts
Receivable policy in Note 2 – Summary of Significant Accounting Policies.
Recently Issued Accounting Pronouncements
In September 2011,
the FASB issued guidance titled “Disclosures about an Employers Participation in a Multiemployer Plan”. The guidance
requires employers that participate in multiemployer pension plans to provide additional quantitative and qualitative disclosures
to provide users with more detailed information about an employer’s involvement in multiemployer pension plans. The guidance
is effective for years ending after December 15, 2011. Adoption of this pronouncement is not expected to have a material impact
on the Company’s consolidated financial statements.
Fair Value of Financial Instruments
The Company’s financial instruments
consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable
approximate their fair value due to the short maturity of these instruments.
2. Inventories
Inventories are comprised as follows:
|
|
March 31, 2012
|
|
|
June 30, 2011
|
|
|
|
|
|
|
|
|
Work-in progress
|
|
$
|
763,016
|
|
|
$
|
820,586
|
|
Component parts
|
|
|
7,599,999
|
|
|
|
7,858,862
|
|
Finished goods
|
|
|
3,285,723
|
|
|
|
3,293,261
|
|
Reserve for obsolete and excess
|
|
|
|
|
|
|
|
|
inventory
|
|
|
(1,310,735
|
)
|
|
|
(1,419,420
|
)
|
|
|
$
|
10,338,003
|
|
|
$
|
10,553,289
|
|
3. Earnings per share
Basic earnings per
share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per
share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during
the period. The number of basic shares outstanding for the three months ended March 31, 2012 and 2011 were 8,124,386 and 8,113,434,
respectively. The number of diluted shares outstanding for the three months ended March 31, 2012 and 2011 were 8,124,386 and 8,195,174,
respectively. The number of basic shares outstanding for the nine months ended March 31, 2012 and 2011 was 8,124,386 and 8,101,643,
respectively. The number of diluted shares outstanding for the nine months ended March 31, 2012 and 2011 was 8,124,386 and 8,121,042,
respectively.
4. Commitments and Contingencies
The Company is subject
to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of
its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking
to interrupt or suspend manufacturing or require any recall or modification of products.
The
Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which,
in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information
currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible
at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse
effect on the Company’s consolidated results of operations, financial position, or cash flows.
Stuyvesant Falls
Power Litigation.
The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid
(“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls,
New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant
Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based
on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices
were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s
claims. Among other things, Niagara seeks approximately $469,000, which it alleges represents the value of electricity provided
prior to the commencement of litigation going back to 2003. As of March 31, 2012, the Company has not recorded a provision for
this matter as management intends to vigorously defend this allegation and believes the payment of this claim is not probable.
The Company believes, however, that any liability it may incur would not have a material adverse effect on its financial condition
or its result of operations.
Armstrong
Medical Infringement Litigation
. The Company is currently involved in litigation against Armstrong Medical Ltd., relating
to the Company’s marketing and sale of Litholyme® and a patent owned by Armstrong Medical regarding a carbon dioxide
absorbent for use in anesthesiology. In this litigation, the Company asserts that Armstrong Medical’s patent is invalid
as being anticipated and obvious in light of material prior art and seeks a declaratory judgment that the marketing and sale of
Litholyme® does not infringe Armstrong Medical’s patent. Armstrong Medical has denied the Company’s claims and
counterclaimed for infringement. As of March 31, 2012, the Company cannot estimate a loss or range of loss for this matter because
damages claimed by Armstrong Medical have not been specified and the proceedings are in early stages.
5. Financing
The Company is party
to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”)
pursuant to which the Company obtained a secured revolving credit facility with borrowing availability of up to $7,500,000 (the
“Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the
Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.
The Credit Facility
was amended on November 11, 2011 extending the maturity date to November 13, 2012. The Credit Facility will be available on a
revolving basis until it expires on November 13, 2012, at which time all amounts outstanding under the Credit Facility will be
due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in
favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to LIBOR plus 3.50%. Advances may be prepaid
in whole or in part without premium or penalty.
Under the Credit Agreement,
advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the
Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability
to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital
stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of
its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are customary
for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when
due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness
of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance
of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure
of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event
of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest
at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed
the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s
obligations under the Credit Facility.
The 90-day LIBOR rate
was 0.47% on March 31, 2012.
At March 31, 2012
the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
The Company was in
compliance with all of the financial covenants associated with the Credit Facility at March 31, 2012.
6. Baralyme®
Agreement
A reconciliation of
deferred revenue resulting from the agreement with Abbott Laboratories (“Abbott”), with the amounts received under
the agreement, and amounts recognized as net sales is as follows:
|
|
Three Months ended
|
|
|
Nine Months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning balance
|
|
$
|
458,800
|
|
|
$
|
1,147,000
|
|
|
$
|
802,900
|
|
|
$
|
1,491,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue recognized as net sales
|
|
|
(172,050
|
)
|
|
|
(172,050
|
)
|
|
|
(516,150
|
)
|
|
|
(516,150
|
)
|
|
|
|
286,750
|
|
|
|
974,950
|
|
|
|
286,750
|
|
|
|
974,950
|
|
Less - Current portion of deferred revenue
|
|
|
(286,750
|
)
|
|
|
(688,200
|
)
|
|
|
(286,750
|
)
|
|
|
(688,200
|
)
|
|
|
$
|
0
|
|
|
$
|
286,750
|
|
|
$
|
0
|
|
|
$
|
286,750
|
|
In addition to
the provisions of the agreement relating to the withdrawal of the Baralyme® product, Abbott has agreed to pay Allied up to
$2,150,000 in product development costs to pursue development of a new carbon dioxide absorption product for use in connection
with inhalation anesthetics that does not contain potassium hydroxide and does not produce a significant exothermic reaction with
currently available inhalation agents. As of March 31, 2012, $2,150,000 has been received as a result of product development activities.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
Results of Operations
Three months ended March 31, 2012 compared to three months
ended March 31, 2011
Allied had net sales
of $10.7 million for the three months ended March 31, 2012, down from net sales of $11.3 million in the prior year same quarter.
Domestic sales were down 10.4% while international sales, which represented 24.5% of third quarter sales, were up 12.9% from the
prior year same quarter.
Sales for the three
months ended March 31, 2012 include $172,050 for the recognition into income of payments resulting from the agreement with Abbott
Laboratories to cease the production and distribution of Baralyme®. Income from the agreement will continue to be recognized
at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell Carbolime® and newly developed
Litholyme®. Both are carbon dioxide absorbents with a different formulation than Baralyme®. The Company ceased the sale
of Baralyme® on August 27, 2004.
Orders for the Company’s
products for the three months ended March 31, 2012 of $10.6 million were $0.1 million or 1.0% higher than orders for the prior
year same quarter of $10.5 million. Domestic orders are down 2.9% over the prior year same quarter while international orders,
which represented 24.7% of third quarter orders, were 17.6% higher than orders for the prior year same quarter. The Company believes
the drop in domestic orders from the prior year is due to normal variations in customer order patterns and does not reflect a
drop in market share or a further drop in aggregate demand.
Gross profit for the
three months ended March 31, 2012 was $2.3 million, or 21.5% of net sales, compared to $2.6 million, or 23.0% of net sales, for
the three months ended March 31, 2011. The decrease in gross profit is primarily the result of lower sales volume. The decrease
in sales for the quarter also resulted in decreased production in comparison to the prior year and less utilization of fixed overhead
cost. Gross profit during the third quarter was favorably impacted from the prior year by an approximately $0.1 million reduction
in shipping and other startup cost at its Stuyvesant Falls facility. The Company continues to implement changes to its operations
to reduce the manufacturing cost in St. Louis and Stuyvesant Falls.
Selling, general and
administrative expenses for the three months ended March 31, 2012 were $2.6 million compared to selling, general and administrative
expenses of $2.5 million for the three months ended March 31, 2011. Research and development costs were approximately $90,000
higher than in the prior year.
Loss from operations
was $0.2 million for the three months ended March 31, 2012 compared to income from operations of $0.1 million for the three months
ended March 31, 2011. Allied had a loss before benefit from income taxes in the third quarter of fiscal 2012 of $0.2 million,
compared to income before provision for income taxes of $0.1 million in the prior year period. The Company recorded a tax benefit
of $89,353 for the three months ended March 31, 2012 compared to a tax provision of $36,972 for the three months ended March 31,
2011.
Net loss for the third
quarter of fiscal 2012 was $145,787 or $0.02 per basic and diluted share compared to net income of $60,324 or $0.01 per basic
and diluted share for the third quarter of fiscal 2011. The weighted average number of common shares outstanding, used in the
calculation of basic earnings per share for the third quarters of fiscal 2012 and 2011 were 8,124,386 and 8,113,434, respectively.
The number of diluted shares outstanding for the three months ended March 31, 2012 and 2011 were 8,124,386 and 8,195,174, respectively.
Nine months ended March 31, 2012 compared to nine months
ended March 31, 2011
Allied had net sales
of $32.8 million for the nine months ended March 31, 2012, down $1.9 million, or 5.5% from net sales of $34.7 million in the prior
year same period resulting from lower order levels. Domestic sales were down 8.3% from the prior year same period while international
sales were up 6.4% from the prior year same period. International business represented 21.6% of sales for the first nine months
of fiscal 2012.
Sales for the nine
months ended March 31, 2012 include $516,150 for the recognition into income of payments resulting from the agreement with Abbott
Laboratories to cease the production and distribution of Baralyme®. Income from the agreement will continue to be recognized
at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell Carbolime® and newly developed
Litholyme®. Both are carbon dioxide absorbents with a different formulation than Baralyme®. The Company ceased the sale
of Baralyme® on August 27, 2004.
Orders for the Company’s
products for the nine months ended March 31, 2012 of $31.3 million were $2.0 million or 6.0% lower than orders for the prior year
same period of $33.3 million. Domestic orders are down 10.9% over the prior year same period while international orders, which
represented 23.8% of orders for the first nine months of fiscal 2012, were 15.4% higher than orders for the prior year same period.
The Company believes the improvement in international orders is due to the reorganization of its international sales efforts.
The Company also continues to make changes to improve the effectiveness of the domestic sales force. The Company believes the
drop in domestic orders from the prior year does not reflect a drop in market share or a further drop in aggregate demand. The
decrease in domestic orders is also partially the result of a decrease in government orders from the prior year. The Company does
not believe this fluctuation in government orders represents a decrease in market share, but represents variation in government
spending from the prior year period.
Gross profit for the
nine months ended March 31, 2012 was $7.5 million, or 22.9% of net sales, compared to $8.0 million, or 23.1% of net sales, for
the nine months ended March 31, 2011. The decrease in gross profit is primarily the result of lower sales than in the prior year.
Gross profit during the first nine months was favorably impacted from the prior year by an approximately $0.2 million reduction
in shipping and other startup cost at its Stuyvesant Falls facility. Gross profit during the first nine months of fiscal 2012
was also favorably impacted by an approximately $0.2 million decrease in fringe benefits. The Company is self-insured for health
care costs and has not changed its fringe benefit plans or providers from the prior year. The Company believes that the reduction
in fringe benefits is primarily due to a reduction in medical claims by employees and their dependents.
Selling, general and
administrative expenses for the nine months ended March 31, 2012 were $7.9 million compared to selling, general and administrative
expenses of $7.8 million for the nine months ended March 31, 2011. Sales commissions are approximately $0.2 million lower than
in the prior year due to the decrease in sales. This decrease has been offset by an increase of legal costs and research and development
costs which are approximately $0.2 million and $0.1 million higher than the prior year, respectively.
Loss from operations
was $0.4 million for the nine months ended March 31, 2012 compared to income from operations of $0.2 million for the nine months
ended March 31, 2011. The Company had a loss before benefit from income taxes in the first nine months of fiscal 2012 of $0.4
million, compared to income before provision for income taxes in the first nine months of fiscal 2011 of $144,648. The Company
recorded a tax benefit of $164,297 for the nine months ended March 31, 2012 compared to a tax provision of $54,966 for the nine
months ended March 31, 2011.
Net loss for the nine
months ended March 31, 2012 was $268,064 or $0.03 per basic and diluted share compared to net income of $89,682 or $0.01 per basic
and diluted share for the first nine months of fiscal 2011. The weighted average number of common shares outstanding, used in
the calculation of basic earnings per share for the first nine months of fiscal 2012 and 2011 were 8,124,386 and 8,101,643, respectively.
The weighted average number of common shares outstanding, used in the calculation of diluted earnings per share for the first
nine months of fiscal 2012 and 2011 were 8,124,386 and 8,121,042, respectively.
Liquidity and
Capital Resources
The Company believes
that available resources and anticipated cash flows from operations are sufficient to meet operating requirements in the coming
year.
The Company’s
working capital was $17.1 million at March 31, 2012 compared to $18.3 million at June 30, 2011. The decrease in working capital
was primarily a result of accounts receivable which decreased by $1.2 million largely due to a decrease in sales. Accounts receivable
as measured in days of sales outstanding (“DSO”) was 33 DSO at March 31, 2012; down from 41 DSO at June 30, 2011.
Cash decreased $0.1 million and inventory decreased by $0.2 million. Other accrued liabilities increased by $0.4 million primarily
as a result of customer prepayments. At March 31, 2012 these decreases in working capital were offset by an increase in other
current assets of $0.5 million due to prepayments to vendors and insurance prepayments. In addition, deferred revenue decreased
by approximately $0.4 million due to amortization of the current portion of the liability.
The Company is party
to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”)
pursuant to which the Company has a secured revolving credit facility with borrowing availability of up to $7,500,000 (the “Credit
Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant
to the terms and subject to the conditions set forth in the Credit Agreement. See Note 5 – Financing to the Company’s
consolidated unaudited financial statements for more information concerning the Credit Facility.
Advances under the
Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust.
Such advances will bear interest at a rate equal to LIBOR plus 3.50%. Advances may be prepaid in whole or in part without premium
or penalty. The 90-day LIBOR rate was 0.47% on March 31, 2012.
At March 31, 2012
the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
In
the event that economic conditions were to severely worsen for a protracted period of time, the Company believes it will have
borrowing capacity under credit facilities that will provide sufficient financial flexibility. The Company would have options
available to ensure liquidity in addition to increased borrowing. Capital expenditures are projected at $2.3 million for the fiscal
year ending June 30, 2012. However, capital expenditures in future years could be postponed.
During
the first nine months of fiscal 2012 the Company has experienced higher prices for raw materials due to increased commodity prices
for brass and thermoplastic resins. Brass cost is driven by higher copper prices, the main component. These increases have been
partially offset by higher revenues for recycled metals and purchasing initiatives for other components and finished goods.
Litigation and Contingencies
The Company becomes,
from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company
believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company’s
product liability insurance.
On May 27, 2011, the
Company filed a declaratory judgment action challenging the validity of a patent owned by Armstrong Medical regarding a carbon
dioxide absorbent for use in anesthesiology and seeking a declaratory judgment that the Company does not infringe such patent.
Among other things, the Company has asserted that Armstrong Medical’s patent is invalid as being anticipated and obvious
in light of material prior art. Armstrong Medical has answered, denying the Company’s claims and counterclaiming that the
Company’s marketing and sale of Litholyme® infringes Armstrong’s patent. See Part II, Item 1. Legal Proceedings,
below for detailed information concerning this litigation. The Company cannot estimate a possible loss or range of loss for this
matter because damages claimed by Armstrong Medical have not been specified and the proceedings are in early stages.
Recently Issued Accounting Guidance
The impact and any
associated risks related to the Company’s critical accounting policies on business operations are discussed throughout “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” where such policies affect our reported and expected
financial results. For a detailed discussion on the application of these and other accounting policies, see the Company’s
Annual Report on Form 10-K for the year ended June 30, 2011.
See Note 1 –
Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact,
if any, on our consolidated financial statements. Management believes there have been no material changes to our critical accounting
policies.
Item 3. Quantitative and Qualitative Disclosure about
Market Risk
At
March 31, 2012, the Company did not have any debt outstanding. The revolving credit facility bears an interest rate using the
90-day LIBOR rate as the basis, as defined in the loan agreement, and therefore is subject to additional expense should there
be an increase in market interest rates.
The Company had no
holdings of derivative financial or commodity instruments at March 31, 2012. The Company has international sales; however these
sales are denominated in U.S. dollars, mitigating foreign exchange rate fluctuation risk.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls
and Procedures
The Company maintains
controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or
submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to
the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions
regarding required disclosure. Based upon their evaluation of those controls and procedures performed as of March 31, 2012, the
Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure controls and procedures were
effective.
Changes in internal control over
financial reporting
There were no changes
in the Company’s internal control over financial reporting during the quarter ended March 31, 2012 that have materially
affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.
Part II. OTHER INFORMATION
Item 1. Legal Proceedings
In response to a “cease and desist
letter” previously received by the Company from Armstrong Medical Ltd., demanding that the Company stop its marketing and
sale of Litholyme®, on May 27, 2011 the Company filed a declaratory judgment action in the United States District Court for
the Eastern District of Missouri against Armstrong Medical. The declaratory judgment action challenges the validity of a patent
owned by Armstrong Medical regarding a carbon dioxide absorbent for use in anesthesiology on the grounds that such patent is anticipated
and obvious in light of material prior art and seeks a declaratory judgment that the Company does not infringe such patent. On
September 15, 2011, Armstrong Medical filed an answer denying the Company’s claims and counterclaiming that the Company’s
marketing and sale of Litholyme® infringes Armstrong’s patent. The Company has filed answers and affirmative defenses
to Armstrong’s counterclaims and the litigation is ongoing.
Item 1A. Risk Factors
Please see the cautionary language
regarding forward-looking statements in the introduction to this Report on Form 10-Q and Part I — Item 1A of our Report
on Form 10-K for the fiscal year ended June 30, 2011, for information regarding risk factors. Other than the additional risk factor
mentioned below, there are no material changes from the risk factors set forth in such Annual Report on Form 10-K as updated by
Part II - Item 1A of our Report on Form 10-Q for the quarter ended December 31, 2011.
Item 6. Exhibits
|
31.1
|
Certification of Chief Executive Officer (filed herewith)
|
|
31.2
|
Certification of Chief Financial Officer (filed herewith)
|
|
32.1
|
Sarbanes-Oxley Certification of Chief Executive Officer
(furnished herewith)*
|
|
32.2
|
Sarbanes-Oxley Certification of Chief Financial Officer
(furnished herewith)*
|
|
99.1
|
Press Release dated May 10, 2012 announcing third quarter
earnings*
|
|
101
|
Pursuant to Rule 405 of Regulation
S-T, the following financial information from the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2012,
is formatted in XBRL interactive data files: (i) Consolidated Statement
of Operations for the three and nine months ended March 31, 2012
and 2011; (ii) Consolidated Balance Sheet at March 31, 2012, and
June 30, 2011; (iii) Consolidated Statement of Cash Flows for the
nine months ended March 31, 2012 and 2011; and (iv) Notes to Financial
Statements.**
|
*Notwithstanding any incorporation of
this Quarterly Report on Form 10-Q in any other filing by the Registrant, Exhibits furnished herewith and designated with an asterisk
(*) shall not be deemed incorporated by reference to any other filing under the Securities Act of 1933 or the Securities Exchange
Act of 1934 unless specifically otherwise set forth therein.
** As provided in Rule 406T of Regulation
S-T, this information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section
18 of the Securities Exchange Act of 1934.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
ALLIED HEALTHCARE PRODUCTS, INC.
|
|
|
|
/s/ Daniel C. Dunn
|
|
Daniel C. Dunn
|
|
Chief Financial Officer
|
|
|
|
Date: May 10, 2012
|
Allied Healthcare Products (NASDAQ:AHPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allied Healthcare Products (NASDAQ:AHPI)
Historical Stock Chart
From Jul 2023 to Jul 2024